Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large‐scale, long‐term cohort study. Issue 5 (May 2016)

• Record Type: Journal Article
• Authors: Nagaoki, Yuko; Aikata, Hiroshi; Nakano, Norihito; Shinohara, Fumi; Nakamura, Yuki; Hatooka, Masahiro; Morio, Kei; Kan, Hiromi; Fujino, Hatsue; Kobayashi, Tomoki; Fukuhara, Takayuki; Masaki, Keiichi; Ono, Atsushi; Nakahara, Takashi; Kawaoka, Tomokazu; Miki, Daiki; Tsuge, Masataka; Hiramatsu, Akira; Imamura, Michio; Takahashi, Shoichi; Kawakami, Yoshiiku; Ochi, Hidenori; Chayama, Kazuaki
• Is Part Of: Journal of gastroenterology and hepatology. Volume 31:Issue 5(2016:May)
• Page Start: 1009
• Page End: 1015
• Publication Date: 2016-05
• Subjects: hepatitis C virus -- hepatocellular carcinoma -- interferon therapy -- sustained viral responders -- α‐fetoprotein; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.13236
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Background: We assessed the risk factors for the development of hepatocellular carcinoma (HCC) following successful eradication of hepatitis C virus (HCV) with interferon (IFN) therapy in a long‐term, large‐scale cohort study. Methods: We reviewed 1094 consecutive patients with HCV who achieved sustained virological response (SVR) following IFN therapy between January 1995 and September 2013. Results: During the observation period (median 50 months: range 13–224), 36 (3%) of 1094 patients developed HCC after SVR. The median period from SVR to diagnosis of HCC was 37 months (range 17–141), and the cumulative rates of HCC at 5, 10, and 15 years were 4%, 6%, and 12%, respectively. Multivariate analysis identified old age (≥60 years, HR, 3.1: 95%CI, 1.3–6.6: P = 0.009), male sex (HR, 12.0: 95%CI, 2.8–50.0: P < 0.0001), advanced fibrosis stage (F3/4, HR, 3.2: 95%CI, 1.6–7.2: P < 0.0001), and alpha‐fetoprotein ≥10 ng/mL at 1 year after SVR (HR, 7.8: 95%CI, 2.9–16.8: P < 0.0001) as significant and independent risk factors for post‐SVR HCC. Conclusions: Older age and male sex (host factors), advanced fibrosis stage (pre‐IFN treatment factor), and higher alpha‐fetoprotein values (post‐treatment factor) were significantly associated with HCC development after HCV eradication.